|
1
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:683–691. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Center MM, Jemal A, Smith RA and Ward E:
Worldwide variations in colorectal cancer. CA Cancer J Clin.
59:366–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zheng R, Zeng H, Zhang S, Chen T and Chen
W: National estimates of cancer prevalence in China, 2011. Cancer
Lett. 370:33–38. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Berg A: Nutrition, development, and
population growth. Popul Bull. 29:3–37. 1973.PubMed/NCBI
|
|
6
|
Alsheridah N and Akhtar S: Diet, obesity
and colorectal carcinoma risk: Results from a national cancer
registry-based middle-eastern study. BMC Cancer. 18:12272018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mafiana RN, Al Lawati AS, Waly MI, Al
Farsi Y, Al Kindi M and Al Moundhri M: Association between dietary
and lifestyle indices and colorectal cancer in Oman: A case-control
study. Asian Pac J Cancer Prev. 19:3117–3122. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Markowitz SD and Bertagnolli MM: Molecular
origins of cancer: Molecular basis of colorectal cancer. N Engl J
Med. 361:2449–2460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dienstmann R, Vermeulen L, Guinney J,
Kopetz S, Tejpar S and Tabernero J: Consensus molecular subtypes
and the evolution of precision medicine in colorectal cancer. Nat
Rev Cancer. 17:2682017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brower V: Connecting viruses to cancer:
How research moves from association to causation. J Natl Cancer
Inst. 96:256–257. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
IARC Working Group on the Evaluation of
Carcinogenic Risks to Humans, . Biological agents. Volume 100 B. A
review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum.
100:1–441. 2012.
|
|
12
|
Tremaroli V and Bäckhed F: Functional
interactions between the gut microbiota and host metabolism.
Nature. 489:242–249. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yamashiro Y: Gut microbiota in health and
disease. Ann Nutr Metab. 71:242–246. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sears CL and Garrett WS: Microbes,
microbiota, and colon cancer. Cell Host Microbe. 15:317–328. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kostic AD, Gevers D, Pedamallu CS, Michaud
M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Tabernero J, et
al: Genomic analysis identifies association of Fusobacterium with
colorectal carcinoma. Genome Res. 22:292–298. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Repass J, Maherali N and Owen K;
Reproducibility Project, : Cancer Biology; Reproducibility Project
Cancer Biology: Registered report: Fusobacterium nucleatum
infection is prevalent in human colorectal carcinoma. ELife.
5(pii): e100122016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yamamura K, Baba Y, Miyake K, Nakamura K,
Shigaki H, Mima K, Kurashige J, Ishimoto T, Iwatsuki M, Sakamoto Y,
et al: Fusobacterium nucleatum in gastroenterological
cancer: Evaluation of measurement methods using quantitative
polymerase chain reaction and a literature review. Oncol Lett.
14:6373–6378. 2017.PubMed/NCBI
|
|
18
|
Han YW: Fusobacterium nucleatum: A
commensal-turned pathogen. Curr Opin Microbiol. 23:141–147. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yamaoka Y, Suehiro Y, Hashimoto S, Hoshida
T, Fujimoto M, Watanabe M, Imanaga D, Sakai K, Matsumoto T,
Nishioka M, et al: Fusobacterium nucleatum as a prognostic
marker of colorectal cancer in a Japanese population. J
Gastroenterol. 53:517–524. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ramos A and Hemann MT: Drugs, Bugs, and
Cancer: Fusobacterium nucleatum promotes chemoresistance in
colorectal cancer. Cell. 170:411–413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang S, Yang Y, Weng W, Guo B, Cai G, Ma
Y and Cai S: Fusobacterium nucleatum promotes
chemoresistance to 5-fluorouracil by upregulation of BIRC3
expressio n in colorectal cancer. J Exp Clin Cancer Res. 38:142019.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Han YW, Shi W, Huang GT, Kinder Haake S,
Park NH, Kuramitsu H and Genco RJ: Interactions between periodontal
bacteria and human oral epithelial cells: Fusobacterium
nucleatum adheres to and invades epithelial cells. Infect
Immun. 68:3140–3146. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Heckmann JG, Lang CJ, Hartl H and Tomandl
B: Multiple brain abscesses caused by Fusobacterium
nucleatum treated conservatively. Can J Neurol Sci. 30:266–268.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Han YW, Fardini Y, Chen C, Iacampo KG,
Peraino VA, Shamonki JM and Redline RW: Term stillbirth caused by
oral Fusobacterium nucleatum. Obstet Gynecol. 115:442–445.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wells CD, Balan V and Smilack JD: Pyogenic
liver abscess after colonoscopy in a patient with ulcerative
colitis. Clin Gastroenterol Hepatol. 3:xxiv2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang X, Buhimschi CS, Temoin S, Bhandari
V, Han YW and Buhimschi IA: Comparative microbial analysis of
paired amniotic fluid and cord blood from pregnancies complicated
by preterm birth and early-onset neonatal sepsis. PLoS One.
8:e561312013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hill GB: Investigating the source of
amniotic fluid isolates of fusobacteria. Clin Infect Dis. 16 (Suppl
4):S423–S424. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Han YW, Redline RW, Li M, Yin L, Hill GB
and McCormick TS: Fusobacterium nucleatum induces premature
and term stillbirths in pregnant mice: Implication of oral bacteria
in preterm birth. Infect Immun. 72:2272–2279. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Han YW: Can oral bacteria cause pregnancy
complications? Womens Health (Lond). 7:401–404. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Han YW: Oral health and adverse pregnancy
outcomes-what's next? J Dent Res. 90:289–293. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu H, Redline RW and Han YW:
Fusobacterium nucleatum induces fetal death in mice via
stimulation of TLR4-mediated placental inflammatory response. J
Immunol. 179:2501–2508. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bachrach G, Ianculovici C, Naor R and
Weiss EI: Fluorescence based measurements of Fusobacterium
nucleatum coaggregation and of fusobacterial attachment to
mammalian cells. FEMS Microbiol Lett. 248:235–240. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shang FM and Liu HL: Fusobacterium
nucleatum and colorectal cancer: A review. World J Gastrointest
Oncol. 10:71–81. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Castellarin M, Warren RL, Freeman JD,
Dreolini L, Krzywinski M, Strauss J, Barnes R, Watson P,
Allen-Vercoe E, Moore RA and Holt RA: Fusobacterium
nucleatum infection is prevalent in human colorectal carcinoma.
Genome Res. 22:299–306. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li YY, Ge QX, Cao J, Zhou YJ, Du YL, Shen
B, Wan YJ and Nie YQ: Association of Fusobacterium nucleatum
infection with colorectal cancer in Chinese patients. World J
Gastroenterol. 22:3227–3233. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mima K, Sukawa Y, Nishihara R, Qian ZR,
Yamauchi M, Inamura K, Kim SA, Masuda A, Nowak JA, Nosho K, et al:
Fusobacterium nucleatum and T cells in colorectal carcinoma.
JAMA Oncol. 1:653–661. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nosho K, Sukawa Y, Adachi Y, Ito M,
Mitsuhashi K, Kurihara H, Kanno S, Yamamoto I, Ishigami K, Igarashi
H, et al: Association of Fusobacterium nucleatum with
immunity and molecular alterations in colorectal cancer. World J
Gastroenterol. 22:557–566. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mima K, Cao Y, Chan AT, Qian ZR, Nowak JA,
Masugi Y, Shi Y, Song M, da Silva A, Gu M, et al: Fusobacterium
nucleatum in colorectal carcinoma tissue according to tumor
location. Clin Transl Gastroenterol. 7:e2002016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Komiya Y, Shimomura Y, Higurashi T, Sugi
Y, Arimoto J, Umezawa S, Uchiyama S, Matsumoto M and Nakajima A:
Patients with colorectal cancer have identical strains of
Fusobacterium nucleatum in their colorectal cancer and oral
cavity. Gut. Jun 22–2018.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bullman S, Pedamallu CS, Sicinska E,
Clancy TE, Zhang X, Cai D, Neuberg D, Huang K, Guevara F, Nelson T,
et al: Analysis of Fusobacterium persistence and antibiotic
response in colorectal cancer. Science. 358:1443–1448. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
McCoy AN, Araújo-Pérez F, Azcárate-Peril
A, Yeh JJ, Sandler RS and Keku TO: Fusobacterium is
associated with colorectal adenomas. PLoS One. 8:e536532013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Amitay EL and Brenner H: Response to
comments on ‘Fusobacterium and colorectal cancer: Causal
factor or passenger? Results from a large colorectal cancer
screening study’. Carcinogenesis. 39:852018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ito M, Kanno S, Nosho K, Sukawa Y,
Mitsuhashi K, Kurihara H, Igarashi H, Takahashi T, Tachibana M,
Takahashi H, et al: Association of Fusobacterium nucleatum
with clinical and molecular features in colorectal serrated
pathway. Int J Cancer. 137:1258–1268. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Koi M, Okita Y and Carethers JM:
Fusobacterium nucleatum infection in colorectal cancer:
Linking inflammation, DNA mismatch repair and genetic and
epigenetic alterations. J Anus Rectum Colon. 2:37–46. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang S, Cai S and Ma Y: Association
between Fusobacterium nucleatum and colorectal cancer:
Progress and future directions. J Cancer. 9:1652–1659. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Coppenhagen-Glazer S, Sol A, Abed J, Naor
R, Zhang X, Han YW and Bachrach G: Fap2 of Fusobacterium
nucleatum is a galactose-inhibitable adhesin involved in
coaggregation, cell adhesion, and preterm birth. Infect Immun.
83:1104–1113. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
West NR, McCuaig S, Franchini F and Powrie
F: Emerging cytokine networks in colorectal cancer. Nat Rev
Immunol. 15:615–629. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Aggarwal BB, Vijayalekshmi RV and Sung B:
Targeting inflammatory pathways for prevention and therapy of
cancer: Short-term friend, long-term foe. Clin Cancer Res.
15:425–430. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Balkwill FR and Mantovani A:
Cancer-related inflammation: Common themes and therapeutic
opportunities. Semin Cancer Biol. 22:33–40. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kostic AD, Chun E, Robertson L, Glickman
JN, Gallini CA, Michaud M, Clancy TE, Chung DC, Lochhead P, Hold
GL, et al: Fusobacterium nucleatum potentiates intestinal
tumorigenesis and modulates the tumor-immune microenvironment. Cell
Host Microbe. 14:207–215. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ma N, Liu Q, Hou L, Wang Y and Liu Z:
MDSCs are involved in the protumorigenic potentials of GM-CSF in
colitis-associated cancer. Int J Immunopathol Pharmacol.
30:152–162. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gabrilovich DI, Ostrand-Rosenberg S and
Bronte V: Coordinated regulation of myeloid cells by tumours. Nat
Rev Immunol. 12:253–268. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Qian BZ and Pollard JW: Macrophage
diversity enhances tumor progression and metastasis. Cell.
141:39–51. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Gabrilovich DI and Nagaraj S:
Myeloid-derived suppressor cells as regulators of the immune
system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Quah SY, Bergenholtz G and Tan KS:
Fusobacterium nucleatum induces cytokine production through
Toll-like-receptor-independent mechanism. Int Endod J. 47:550–559.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Dharmani P, Strauss J, Ambrose C,
Allen-Vercoe E and Chadee K: Fusobacterium nucleatum
infection of colonic cells stimulates MUC2 mucin and tumor necrosis
factor alpha. Infect Immun. 79:2597–2607. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Trinchieri G: Cancer and inflammation: An
old intuition with rapidly evolving new concepts. Annu Rev Immunol.
30:677–706. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Taniguchi K and Karin M: NF-κB,
inflammation, immunity and cancer: Coming of age. Nat Rev Immunol.
18:309–324. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Fardini Y, Wang X, Témoin S, Nithianantham
S, Lee D, Shoham M and Han YW: Fusobacterium nucleatum
adhesin FadA binds vascular endothelial cadherin and alters
endothelial integrity. Mol Microbiol. 82:1468–1480. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Han YW, Ikegami A, Rajanna C, Kawsar HI,
Zhou Y, Li M, Sojar HT, Genco RJ, Kuramitsu HK and Deng CX:
Identification and characterization of a novel adhesin unique to
oral fusobacteria. J Bacteriol. 187:5330–5340. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Xu M, Yamada M, Li M, Liu H, Chen SG and
Han YW: FadA from Fusobacterium nucleatum utilizes both
secreted and nonsecreted forms for functional oligomerization for
attachment and invasion of host cell. J Biol Chem. 282:25000–25009.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Temoin S, Wu KL, Wu V, Shoham M and Han
YW: Signal peptide of FadA adhesin from Fusobacterium
nucleatum plays a novel structural role by modulating the
filament's length and width. FEBS Lett. 586:1–6. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Rubinstein MR, Wang X, Liu W, Hao Y, Cai G
and Han YW: Fusobacterium nucleatum promotes colorectal
carcinogenesis by modulating E-cadherin/β-catenin signaling via its
FadA adhesin. Cell Host Microbe. 14:195–206. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Chen Y, Peng Y, Yu J, Chen T, Wu Y, Shi L,
Li Q, Wu J and Fu X: Invasive Fusobacterium nucleatum
activates beta-catenin signaling in colorectal cancer via a
TLR4/P-PAK1 cascade. Oncotarget. 8:31802–31814. 2017.PubMed/NCBI
|
|
65
|
Wu Y, Wu J, Chen T, Li Q, Peng W, Li H,
Tang X and Fu X: Fusobacterium nucleatum potentiates
intestinal tumorigenesis in mice via a Toll-like receptor
4/p21-activated kinase 1 cascade. Dig Dis Sci. 63:1210–1218. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Jiang WG, Sanders AJ, Katoh M, Ungefroren
H, Gieseler F, Prince M, Thompson SK, Zollo M, Spano D, Dhawan P,
et al: Tissue invasion and metastasis: Molecular, biological and
clinical perspectives. Semin Cancer Biol. 35 (Suppl):S244–S275.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Abed J, Emgård JE, Zamir G, Faroja M,
Almogy G, Grenov A, Sol A, Naor R, Pikarsky E, Atlan KA, et al:
Fap2 Mediates Fusobacterium nucleatum colorectal
adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc.
Cell Host Microbe. 20:215–225. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Gur C, Ibrahim Y, Isaacson B, Yamin R,
Abed J, Gamliel M, Enk J, Bar-On Y, Stanietsky-Kaynan N,
Coppenhagen-Glazer S, et al: Binding of the Fap2 protein of
Fusobacterium nucleatum to human inhibitory receptor TIGIT
protects tumors from immune cell attack. Immunity. 42:344–355.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Shenker BJ and Datar S: Fusobacterium
nucleatum inhibits human T-cell activation by arresting cells
in the mid-G1 phase of the cell cycle. Infect Immun. 63:4830–4836.
1995.PubMed/NCBI
|
|
70
|
Yang Y, Weng W, Peng J, Hong L, Yang L,
Toiyama Y, Gao R, Liu M, Yin M, Pan C, et al: Fusobacterium
nucleatum increases proliferation of colorectal cancer cells
and tumor development in mice by activating Toll-like receptor 4
signaling to nuclear factor-κB, and up-regulating expression of
microRNA-21. Gastroenterology. 152:851–866.e24. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Tahara T, Yamamoto E, Suzuki H, Maruyama
R, Chung W, Garriga J, Jelinek J, Yamano HO, Sugai T, An B, et al:
Fusobacterium in colonic flora and molecular features of
colorectal carcinoma. Cancer Res. 74:1311–1318. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Mima K, Nishihara R, Qian ZR, Cao Y,
Sukawa Y, Nowak JA, Yang J, Dou R, Masugi Y, Song M, et al:
Fusobacterium nucleatum in colorectal carcinoma tissue and
patient prognosis. Gut. 65:1973–1980. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Ryuk JP, Choi GS, Park JS, Kim HJ, Park
SY, Yoon GS, Jun SH and Kwon YC: Predictive factors and the
prognosis of recurrence of colorectal cancer within 2 years after
curative resection. Ann Surg Treat Res. 86:143–151. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Cartwright TH: Treatment decisions after
diagnosis of metastatic colorectal cancer. Clin Colorectal Cancer.
11:155–166. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Yu T, Guo F, Yu Y, Sun T, Ma D, Han J,
Qian Y, Kryczek I, Sun D, Nagarsheth N, et al: Fusobacterium
nucleatum promotes chemoresistance to colorectal cancer by
modulating autophagy. Cell. 170:548–563.e16. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Lasry A, Zinger A and Ben-Neriah Y:
Inflammatory networks underlying colorectal cancer. Nat Immunol.
17:230–240. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Huang WW, Hsieh KP, Huang RY and Yang YH:
Role of cyclooxygenase-2 inhibitors in the survival outcome of
colorectal cancer patients: A population-based cohort study.
Kaohsiung J Med Sci. 33:308–314. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Williams CS, Shattuck-Brandt RL and DuBois
RN: The role of COX-2 in intestinal cancer. Expert Opin Investig
Drugs. 8:1–12. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Waddell WR, Ganser GF, Cerise EJ and
Loughry RW: Sulindac for polyposis of the colon. Am J Surg.
157:175–179. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Rothwell PM, Wilson M, Elwin CE, Norrving
B, Algra A, Warlow CP and Meade TW: Long-term effect of aspirin on
colorectal cancer incidence and mortality: 20-year follow-up of
five randomised trials. Lancet. 376:1741–1750. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Tsoi KK, Chan FC, Hirai HW and Sung JJ:
Risk of gastrointestinal bleeding and benefit from colorectal
cancer reduction from long-term use of low-dose aspirin: A
retrospective study of 612 509 patients. J Gastroenterol Hepatol.
33:1728–1736. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Johnson CC, Jankowski M, Rolnick S, Yood
MU and Alford SH: Influence of NSAID use among colorectal cancer
survivors on cancer outcomes. Am J Clin Oncol. 40:370–374. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Sandler RS, Halabi S, Baron JA, Budinger
S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi
CL, et al: A randomized trial of aspirin to prevent colorectal
adenomas in patients with previous colorectal cancer. N Engl J Med.
348:883–890. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Ng K, Meyerhardt JA, Chan AT, Sato K, Chan
JA, Niedzwiecki D, Saltz LB, Mayer RJ, Benson AB III, Schaefer PL,
et al: Aspirin and COX-2 inhibitor use in patients with stage III
colon cancer. J Natl Cancer Inst. 107:3452014.PubMed/NCBI
|
|
85
|
Bos CL, Kodach LL, van den Brink GR, Diks
SH, van Santen MM, Richel DJ, Peppelenbosch MP and Hardwick JC:
Effect of aspirin on the Wnt/beta-catenin pathway is mediated via
protein phosphatase 2A. Oncogene. 25:6447–6456. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Ma X, Aoki T, Tsuruyama T and Narumiya S:
Definition of prostaglandin E2-EP2 signals in the colon tumor
microenvironment that amplify inflammation and tumor growth. Cancer
Res. 75:2822–2832. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Haak BW, Lankelma JM, Hugenholtz F, Belzer
C, de Vos WM and Wiersinga WJ: Long-term impact of oral vancomycin,
ciprofloxacin and metronidazole on the gut microbiota in healthy
humans. J Antimicrob Chemother. 74:782–786. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Yu YN, Yu TC, Zhao HJ, Sun TT, Chen HM,
Chen HY, An HF, Weng YR, Yu J, Li M, et al: Berberine may rescue
Fusobacterium nucleatum-induced colorectal tumorigenesis by
modulating the tumor microenvironment. Oncotarget. 6:32013–32026.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Bever KM and Le DT: An expanding role for
immunotherapy in colorectal cancer. J Natl Compr Canc Netw.
15:401–410. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Bhatt AP, Redinbo MR and Bultman SJ: The
role of the microbiome in cancer development and therapy. CA Cancer
J Clin. 67:326–344. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Chakravarty D, Gao J, Phillips SM, Kundra
R, Zhang H, Wang J, Rudolph JE, Yaeger R, Soumerai T, Nissan MH, et
al: OncoKB: A precision oncology knowledge base. JCO Precis Oncol
2017. 2017. View Article : Google Scholar
|
|
92
|
Cramer P and Bresalier RS:
Gastrointestinal and hepatic complications of immune checkpoint
inhibitors. Curr Gastroenterol Rep. 19:32017. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Nedaeinia R, Sharifi M, Avan A, Kazemi M,
Nabinejad A, Ferns GA, Ghayour-Mobarhan M and Salehi R: Inhibition
of microRNA-21 via locked nucleic acid-anti-miR suppressed
metastatic features of colorectal cancer cells through modulation
of programmed cell death 4. Tumour Biol. 39:10104283176922612017.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Kumar A, Thotakura PL, Tiwary BK and
Krishna R: Target identification in Fusobacterium nucleatum
by subtractive genomics approach and enrichment analysis of
host-pathogen protein-protein interactions. BMC Microbiol.
16:842016. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Brook I and Frazier EH: Immune response to
Fusobacterium nucleatum and Prevotella intermedia in the
sputum of patients with acute exacerbation of chronic bronchitis.
Chest. 124:832–833. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Velsko IM, Chukkapalli SS, Rivera-Kweh MF,
Chen H, Zheng D, Bhattacharyya I, Gangula PR, Lucas AR and Kesavalu
L: Fusobacterium nucleatum alters atherosclerosis risk
factors and enhances inflammatory markers with an atheroprotective
immune response in ApoE(null) mice. PLoS One. 10:e01297952015.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Wang HF, Li LF, Guo SH, Zeng QY, Ning F,
Liu WL and Zhang G: Evaluation of antibody level against
Fusobacterium nucleatum in the serological diagnosis of
colorectal cancer. Sci Rep. 6:334402016. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Hundt S, Haug U and Brenner H: Comparative
evaluation of immunochemical fecal occult blood tests for
colorectal adenoma detection. Ann Intern Med. 150:162–169. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Wong SH, Kwong TNY, Chow TC, Luk AKC, Dai
RZW, Nakatsu G, Lam TYT, Zhang L, Wu JCY, Chan FKL, et al:
Quantitation of faecal Fusobacterium improves faecal
immunochemical test in detecting advanced colorectal neoplasia.
Gut. 66:1441–1448. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Huang S, Yang Z, Zou D, Dong D, Liu A, Liu
W and Huang L: Rapid detection of nusG and fadA in Fusobacterium
nucleatum by loop-mediated isothermal amplification. J Med
Microbiol. 65:760–769. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Song M, Garrett WS and Chan AT: Nutrients,
foods, and colorectal cancer prevention. Gastroenterology.
148:1244–1260.e16. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Norat T, Bingham S, Ferrari P, Slimani N,
Jenab M, Mazuir M, Overvad K, Olsen A, Tjønneland A, Clavel F, et
al: Meat, fish, and colorectal cancer risk: The European
prospective investigation into cancer and nutrition. J Natl Cancer
Inst. 97:906–916. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Larsson SC and Wolk A: Meat consumption
and risk of colorectal cancer: A meta-analysis of prospective
studies. Int J Cancer. 119:2657–2664. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Magalhães B, Peleteiro B and Lunet N:
Dietary patterns and colorectal cancer: Systematic review and
meta-analysis. Eur J Cancer Prev. 21:15–23. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
David LA, Maurice CF, Carmody RN,
Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y,
Fischbach MA, et al: Diet rapidly and reproducibly alters the human
gut microbiome. Nature. 505:559–563. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Xu Z and Knight R: Dietary effects on
human gut microbiome diversity. Br J Nutr. 113 (Suppl):S1–S5. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Haro C, García-Carpintero S, Rangel-Zúñiga
OA, Alcalá-Díaz JF, Landa BB, Clemente JC, Pérez-Martínez P,
López-Miranda J, Pérez-Jiménez F and Camargo A: Consumption of two
healthy dietary patterns restored microbiota dysbiosis in obese
patients with metabolic dysfunction. Mol Nutr Food Res. 61:2017.
View Article : Google Scholar
|
|
108
|
Sonnenburg ED, Smits SA, Tikhonov M,
Higginbottom SK, Wingreen NS and Sonnenburg JL: Diet-induced
extinctions in the gut microbiota compound over generations.
Nature. 529:212–215. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Tabung FK, Liu L, Wang W, Fung TT, Wu K,
Smith-Warner SA, Cao Y, Hu FB, Ogino S, Fuchs CS and Giovannucci
EL: Association of dietary inflammatory potential with colorectal
cancer risk in men and women. JAMA Oncol. 4:366–373. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Tabung FK, Smith-Warner SA, Chavarro JE,
Wu K, Fuchs CS, Hu FB, Chan AT, Willett WC and Giovannucci EL:
Development and validation of an empirical dietary inflammatory
index. J Nutr. 146:1560–1570. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Liu L, Tabung FK, Zhang X, Nowak JA, Qian
ZR, Hamada T, Nevo D, Bullman S, Mima K, Kosumi K, et al: Diets
that promote colon inflammation associate with risk of colorectal
carcinomas that contain Fusobacterium nucleatum. Clin
Gastroenterol Hepatol. 16:1622–1631.e3. 2018. View Article : Google Scholar : PubMed/NCBI
|
